Page 22 - Ace2 News Today

Startup develops yeast-based test to detect the presence of SARS-CoV-2 in saliva Incubated at the University of Campinas (UNICAMP) in the state of São Paulo, Brazil, and supported by São Paulo Research Foundation- FAPESPs Innovative Research in Small Business Program (PIPE), BIOinFOOD is a startup that is developing a rapid COVID-19 diagnostic test based on a patent application filed by students at UNICAMPs Genomics and Bioenergy Laboratory. The test is based on a biosensor consisting of a ge...

Indias Covaxin Neutralizes UK Variant of Covid by Hannah Joy on  January 28, 2021 at 12:39 PM Covaxin can now neutralize UK variants of SARS-CoV-2 effectively by reducing the possibility of mutant virus escape. Covaxin is developed Bharat Biotech in Hyderabad, India. According to the research paper carried by bioRxiv, the preprint server for biology, the study has dispelled the uncertainty of possible neutralization escape. A group of researchers from Indian Council of Medica...

Now, in new research posted to the preprint server bioRxiv*, scientists use an experimental structure of the Spike RBD domain co-crystallized with part of the ACE2 receptor and several in silico methods to analyze the possible impacts of three amino acid replacements (Spike K417N, E484K, N501Y) concerning ACE2 binding.

Using more than 100,000 virus genome sequences uploaded in the GISAID database, researchers found around 9,000 mutations in the virus spike protein RBD.

Researchers studying the effect of convalescent sera and monoclonal antibodies from recovered patients found the UK and South African SARS-CoV-2 variants are more resistant to neutralization compared to the wild-type virus.

Recently a team of researchers from Saudi Arabia, the United Arab Emirates, and the United States assessed travel-related anxiety in healthcare workers (HCWs) considering the emergence of new variants caused by SARS-CoV-2 mutations.

A team of international scientists has recently developed a bispecific antibody that can bind two non-overlapping regions of the spike receptor-binding domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and completely prevent the viral-host interaction.

A team of international scientists has demonstrated that therapeutic inhibition of a transcriptional regulator BRD2, required for the endogenous expression of angiotensin-converting enzyme 2 (ACE2), can potentially suppress severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The study is currently available on the bioRxiv* preprint server.

Promising nanobodies against COVID-19 produced by llamas Thought LeadersDr. David BrodyProfessor of NeurologyUniformed Services University In this interview, News-Medical speaks to Dr. David Brody about his latest research that involved discovering nanobodies produced by llamas that could help combat coronavirus. What provoked your research into the ongoing COVID-19 pandemic? We are neuroscientists, so it was a bit of a shift in direction! For several years TJ and I had been testing out how to...

Renal cell carcinoma (RCC) is the most common form of cancer of the kidney. In 2018, there were an estimated 403,000 new cases of RCC and 175,000 deaths due to kidney cancer worldwide.